Page 56 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

via scavenging free radicals and ameliorating myocardial through an anti-apoptosis mechanism driven by modulation
microenvironment. Nano Today. 2022;46:101589. of ferrous iron. Nat Commun. 2022;13(1):7778.
doi: 10.1016/j.nantod.2022.101589 doi: 10.1038/s41467-022-35503-y
67. Hao T, Li J, Yao F, et al. Injectable fullerenol/alginate 78. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-241.
hydrogel for suppression of oxidative stress damage in doi: 10.1038/35025203
brown adipose-derived stem cells and cardiac repair. ACS
Nano. 2017;11(6):5474-5488. 79. Libby P, Ridker PM, Hansson GK. Progress and challenges
in translating the biology of atherosclerosis. Nature.
doi: 10.1021/acsnano.7b00221
2011;473(7347):317-325.
68. Im GB, Kim YG, Yoo TY, et al. Ceria nanoparticles as copper
chaperones that activate SOD1 for synergistic antioxidant doi: 10.1038/nature10146
therapy to treat ischemic vascular diseases. Adv Mater. 80. Weber C, Noels H. Atherosclerosis: Current pathogenesis
2023;35(16):e2208989. and therapeutic options. Nat Med. 2011;17(11):1410-1422.
doi: 10.1002/adma.202208989 doi: 10.1038/nm.2538
69. Pagliari F, Mandoli C, Forte G, et al. Cerium oxide 81. Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis:
nanoparticles protect cardiac progenitor cells from oxidative Vascular intrinsic and extrinsic factors and potential role of
stress. ACS Nano. 2012;6(5):3767-3775. IL-6. Nat Rev Cardiol. 2021;18(1):58-68.
doi: 10.1021/nn2048069 doi: 10.1038/s41569-020-0431-7
70. Blum RH, Carter SK. Adriamycin. A new anticancer 82. Koelwyn GJ, Corr EM, Erbay E, Moore KJ. Regulation of
drug with significant clinical activity. Ann Intern Med. macrophage immunometabolism in atherosclerosis. Nat
1974;80(2):249-259. Immunol. 2018;19(6):526-537.
doi: 10.7326/0003-4819-80-2-249 doi: 10.1038/s41590-018-0113-3
71. Singal PK, Iliskovic N. Doxorubicin-induced 83. Thomas SR, Witting PK, Stocker R. A role for reduced coenzyme
cardiomyopathy. N Engl J Med. 1998;339(13):900-905. Q in atherosclerosis? Biofactors. 1999;9(2-4):207-224.
doi: 10.1056/NEJM199809243391307 doi: 10.1002/biof.5520090216
72. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 84. Salonen RM, Nyyssonen K, Kaikkonen J, et al. Six-year
Anthracyclines: Molecular advances and pharmacologic effect of combined vitamin C and E supplementation
developments in antitumor activity and cardiotoxicity. on atherosclerotic progression: The antioxidant
Pharmacol Rev. 2004;56(2):185-229. supplementation in atherosclerosis prevention (ASAP)
study. Circulation. 2003;107(7):947-953.
doi: 10.1124/pr.56.2.6
doi: 10.1161/01.cir.0000050626.25057.51
73. Fang X, Wang H, Han D, et al. Ferroptosis as a target for
protection against cardiomyopathy. Proc Natl Acad Sci U S 85. Zimetbaum P, Eder H, Frishman W. Probucol: Pharmacology
A. 2019;116(7):2672-2680. and clinical application. J Clin Pharmacol. 1990;30(1):3-9.
doi: 10.1073/pnas.1821022116 doi: 10.1002/j.1552-4604.1990.tb03431.x
74. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer 86. Yamakoshi J, Kataoka S, Koga T, Ariga T. Proanthocyanidin-
R. Nanocarriers as an emerging platform for cancer therapy. rich extract from grape seeds attenuates the development
Nat Nanotechnol. 2007;2(12):751-760. of aortic atherosclerosis in cholesterol-fed rabbits.
Atherosclerosis. 1999;142(1):139-149.
doi: 10.1038/nnano.2007.387
doi: 10.1016/s0021-9150(98)00230-5
75. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: An update
on anticancer molecular action, toxicity and novel drug 87. Kim CH, Mitchell JB, Bursill CA, et al. The nitroxide radical
delivery systems. J Pharm Pharmacol. 2013;65(2):157-170. TEMPOL prevents obesity, hyperlipidaemia, elevation of
inflammatory cytokines, and modulates atherosclerotic plaque
doi: 10.1111/j.2042-7158.2012.01567.x
composition in apoE-/- mice. Atherosclerosis. 2015;240(1):234-241.
76. Park S, Yoon J, Bae S, et al. Therapeutic use of H2O2-responsive
anti-oxidant polymer nanoparticles for doxorubicin-induced doi: 10.1016/j.atherosclerosis.2015.03.012
cardiomyopathy. Biomaterials. 2014;35(22):5944-5953. 88. Sugamura K, Keaney JF Jr. Reactive oxygen species in
cardiovascular disease. Free Radic Biol Med. 2011;51(5):978-992.
doi: 10.1016/j.biomaterials.2014.03.084
doi: 10.1016/j.freeradbiomed.2011.05.004
77. Huo M, Tang Z, Wang L, et al. Magnesium hexacyanoferrate
nanocatalysts attenuate chemodrug-induced cardiotoxicity 89. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives

Volume 1 Issue 1 (2024) 50 doi: 10.36922/imo.2527